{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:07:49Z","timestamp":1792066069659,"version":"4.4.0"},"reference-count":28,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,1,1]],"date-time":"2024-01-01T00:00:00Z","timestamp":1704067200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82293684"],"award-info":[{"award-number":["82293684"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004826","name":"Natural Science Foundation of Beijing Municipality","doi-asserted-by":"publisher","award":["L232084"],"award-info":[{"award-number":["L232084"]}],"id":[{"id":"10.13039\/501100004826","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012166","name":"National Key Research and Development Program of China","doi-asserted-by":"publisher","award":["2022YFA0806400"],"award-info":[{"award-number":["2022YFA0806400"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinica Chimica Acta"],"published-print":{"date-parts":[[2024,1]]},"DOI":"10.1016\/j.cca.2023.117707","type":"journal-article","created":{"date-parts":[[2023,12,14]],"date-time":"2023-12-14T17:09:34Z","timestamp":1702573774000},"page":"117707","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Detection of lenalidomide metabolites in urine to discover drug-resistant compounds"],"prefix":"10.1016","volume":"553","author":[{"given":"Xiaokai","family":"Zhan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xikun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Rang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Man","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiajia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ran","family":"Tang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sibin","family":"Fan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fengyi","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoying","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhongxia","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"14","key":"10.1016\/j.cca.2023.117707_b0005","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1038\/s41586-019-1730-1","article-title":"A view on drug resistance in cancer","volume":"575","author":"Vasan","year":"2019","journal-title":"Nature"},{"issue":"5","key":"10.1016\/j.cca.2023.117707_b0010","article-title":"Guidelines for diagnosis and treatment of multiple myeloma in China (revised in 2020)","volume":"59","author":"Huang","year":"2020","journal-title":"Chin J Intern Med"},{"issue":"12","key":"10.1016\/j.cca.2023.117707_b0015","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.1021\/tx400226u","article-title":"Framework for identifying chemicals with structural features associated with the potential to act as developmental or reproductive toxicants","volume":"26","author":"Wu","year":"2013","journal-title":"Chem Res Toxicol."},{"issue":"1","key":"10.1016\/j.cca.2023.117707_b0020","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1002\/anie.201609655","article-title":"Small molecule microarray based discovery of PARP14 inhibitors","volume":"56","author":"Peng","year":"2017","journal-title":"Angew Chem Int Ed Engl."},{"issue":"25","key":"10.1016\/j.cca.2023.117707_b0025","doi-asserted-by":"crossref","first-page":"4557","DOI":"10.1021\/acs.orglett.2c01659","article-title":"Synthesis and spectral properties of aggregation-induced emission-active push-pull chromophores based on isoindole scaffolds","volume":"24","author":"Yu","year":"2022","journal-title":"Org Lett."},{"issue":"20","key":"10.1016\/j.cca.2023.117707_b0030","doi-asserted-by":"crossref","first-page":"4091","DOI":"10.1039\/D2OB00519K","article-title":"Ni-catalysed deamidative fluorination of amides with electrophilic fluorinating reagents","volume":"20","author":"Wu","year":"2022","journal-title":"Org Biomol Chem."},{"issue":"6","key":"10.1016\/j.cca.2023.117707_b0035","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1002\/jssc.201701211","article-title":"Chiral separation of lenalidomide by liquid chromatography on polysaccharide-type stationary phases and by capillary electrophoresis using cyclodextrin selectors","volume":"41","author":"Szab\u00f3","year":"2018","journal-title":"J Sep Sci."},{"issue":"3","key":"10.1016\/j.cca.2023.117707_b0040","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-011-1760-3","article-title":"Pharmacokinetics, metabolism and excretion of [(14)C]-lenalidomide following oral administration in healthy male subjects","volume":"69","author":"Chen","year":"2012","journal-title":"Cancer Chemother Pharmacol."},{"key":"10.1016\/j.cca.2023.117707_b0045","unstructured":"Celgene Corporation. Revlimid (lenalidomide) capsules prescribing information. Summit, NJ; 2021 Aug."},{"issue":"7","key":"10.1016\/j.cca.2023.117707_b0050","doi-asserted-by":"crossref","first-page":"1238","DOI":"10.1080\/10428190802005191","article-title":"Thalidomide and lenalidomide: Mechanism-based potential drug combinations","volume":"49","author":"Vallet","year":"2008","journal-title":"Leuk. Lymphoma"},{"issue":"24","key":"10.1016\/j.cca.2023.117707_b0055","doi-asserted-by":"crossref","first-page":"2146","DOI":"10.1182\/blood.2019003749","article-title":"Aromatase is a novel neosubstrate of cereblon responsible for immunomodulatory drug induced thrombocytopenia","volume":"135","author":"Tochigi","year":"2020","journal-title":"Blood"},{"issue":"5971","key":"10.1016\/j.cca.2023.117707_b0060","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"18","key":"10.1016\/j.cca.2023.117707_b0065","doi-asserted-by":"crossref","first-page":"4771","DOI":"10.1182\/blood-2011-05-356063","article-title":"Cereblon expression is required for the antimyeloma activity of lenalidomide and pomalidomide","volume":"118","author":"Zhu","year":"2011","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.cca.2023.117707_b0070","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","article-title":"Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide","volume":"26","author":"Lopez-Girona","year":"2012","journal-title":"Leukemia"},{"issue":"4","key":"10.1016\/j.cca.2023.117707_b0075","doi-asserted-by":"crossref","first-page":"624","DOI":"10.1182\/blood-2012-06-438101","article-title":"High cereblon expression is associated with better survival in patients with newly diagnosed multiple myeloma treated with thalidomide maintenance","volume":"121","author":"Broyl","year":"2013","journal-title":"Blood"},{"issue":"5","key":"10.1016\/j.cca.2023.117707_b0080","doi-asserted-by":"crossref","first-page":"695","DOI":"10.1111\/bjh.12338","article-title":"High expression of cereblon (CRBN) is associated with improved clinical response in patients with multiple myeloma treated with lenalidomide and dexamethasone","volume":"161","author":"Heintel","year":"2013","journal-title":"Br. J. Haematol."},{"issue":"4","key":"10.1016\/j.cca.2023.117707_b0085","doi-asserted-by":"crossref","first-page":"536","DOI":"10.1182\/blood-2014-02-557819","article-title":"Identification of cereblonbinding proteins and relationship with response and survival after IMiDs in multiple myeloma","volume":"124","author":"Zhu","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.cca.2023.117707_b0090","first-page":"122","article-title":"RNA- sequencing of pair pretreatment and relapse samples reveals differentially expressed genes associated with lenalidomide resistance in multiple myeloma [J]","author":"Nei","year":"2013","journal-title":"Blood (ASH Annual Meeting Abstract)"},{"key":"10.1016\/j.cca.2023.117707_b0095","doi-asserted-by":"crossref","first-page":"11009","DOI":"10.1074\/jbc.M110.180208","article-title":"Evidence of a role for activation of Wnt\/beta-catenin signaling in the resistance of plasma cells to lenalidomide","volume":"286","author":"Bjorklund","year":"2011","journal-title":"J Biol Chem."},{"key":"10.1016\/j.cca.2023.117707_b0100","doi-asserted-by":"crossref","first-page":"373","DOI":"10.1038\/leu.2013.174","article-title":"Evidence of a role for CD44 and cell adhesion in mediating resistance to lenalidomide in multiple myeloma: therapeutic implications","volume":"28","author":"Bjorklund","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.cca.2023.117707_b0105","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.phytochem.2012.06.015","article-title":"Biotransformation of columbianadin by rat hepatic microsomes and inhibition of biotransformation products on NO production in RAW 264.7 cells in vitro [J]","volume":"81","author":"Zhang","year":"2012","journal-title":"Phytochemistry"},{"key":"10.1016\/j.cca.2023.117707_b0110","doi-asserted-by":"crossref","first-page":"88","DOI":"10.1016\/j.fitote.2013.12.017","article-title":"Biotransformation of isoimperatorin by rat liver microsomes and its quantification by LC-MS\/MS method [J]","volume":"93","author":"Chen","year":"2014","journal-title":"Fitoterapia"},{"issue":"2","key":"10.1016\/j.cca.2023.117707_b0115","doi-asserted-by":"crossref","first-page":"216","DOI":"10.1002\/bmc.1276","article-title":"A new metabolite of nodakenetin by rat liver microsomes and its quantification by RP-HPLC method [J]","volume":"24","author":"Zhang","year":"2010","journal-title":"Biomed Chromatogr"},{"key":"10.1016\/j.cca.2023.117707_b0120","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00280-011-1760-3","article-title":"Pharmacokinetics, metabolism and excretion of [14C]-lenalidomide following oral administration in healthy male subjects","volume":"69","author":"Chen","year":"2012","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cca.2023.117707_b0125","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1007\/s40262-016-0432-1","article-title":"Clinical Pharmacokinetics and Pharmacodynamics of Lenalidomide","volume":"56","author":"Chen","year":"2017","journal-title":"Clin Pharmacokinet"},{"key":"10.1016\/j.cca.2023.117707_b0130","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1007\/s00280-008-0867-7","article-title":"Lenalidomide: in vitro evaluation of the metabolism and assessment of cytochrome P450 inhibition and induction","volume":"63","author":"Kumar","year":"2009","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cca.2023.117707_b0135","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1007\/s00280-016-3228-y","article-title":"Population pharmacokinetics of lenalidomide in multiple myeloma patients","volume":"79","author":"Guglieri-L\u00f3pez","year":"2017","journal-title":"Cancer Chemother Pharmacol"},{"key":"10.1016\/j.cca.2023.117707_b0140","doi-asserted-by":"crossref","first-page":"156","DOI":"10.1016\/j.jpba.2012.10.018","article-title":"Investigation of the biotransformation of osthole by liquid chromatography\/tandem mass spectrometry","volume":"74","author":"Li","year":"2013","journal-title":"J. Pharm. Biomed. Anal."}],"container-title":["Clinica Chimica Acta"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123005090?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0009898123005090?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,2]],"date-time":"2025-11-02T20:06:45Z","timestamp":1762114005000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0009898123005090"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,1]]},"references-count":28,"alternative-id":["S0009898123005090"],"URL":"https:\/\/doi.org\/10.1016\/j.cca.2023.117707","relation":{},"ISSN":["0009-8981"],"issn-type":[{"value":"0009-8981","type":"print"}],"subject":[],"published":{"date-parts":[[2024,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Detection of lenalidomide metabolites in urine to discover drug-resistant compounds","name":"articletitle","label":"Article Title"},{"value":"Clinica Chimica Acta","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cca.2023.117707","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"117707"}}